NURO - NeuroMetrix, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.4200
-0.0600 (-4.05%)
As of 9:55AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close1.4800
Open1.4500
Bid1.4100 x 3100
Ask1.4200 x 1300
Day's Range1.4000 - 1.4500
52 Week Range1.2000 - 3.0900
Volume229,506
Avg. Volume193,740
Market Cap10.447M
Beta-0.22
PE Ratio (TTM)N/A
EPS (TTM)-3.7390
Earnings DateOct 18, 2017 - Oct 23, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2007-03-28
1y Target Est3.00
Trade prices are not sourced from all markets
  • ACCESSWIRE2 hours ago

    Today's Research Reports on Stocks to Watch: Neptune Technologies & Bioressources and NeuroMetrix

    NEW YORK, NY / ACCESSWIRE / June 20, 2018 / It was a multi-year extraction agreement with Canopy Growth that sent shares of Neptune Technologies flying higher on Tuesday. Shares of NeuroMetrix also scored ...

  • Benzingayesterday

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Neurometrix Inc (NASDAQ: NURO ) stock was trading ...

  • GlobeNewswireyesterday

    NeuroMetrix Receives $3.8M Milestone Payment Under Its Collaboration with GSK Consumer Healthcare

    NeuroMetrix, Inc. (NURO), today reported that it had achieved the first development milestone under its strategic collaboration with GSK Consumer Healthcare. A milestone payment of $3.8 Million was made by GSK. In addition, NeuroMetrix and GSK will co-fund Quell technology development for an initial two-year period starting in 2019 with extensions by mutual agreement.

  • Is NeuroMetrix Inc’s (NASDAQ:NURO) CEO Paid At A Competitive Rate?
    Simply Wall St.9 days ago

    Is NeuroMetrix Inc’s (NASDAQ:NURO) CEO Paid At A Competitive Rate?

    Shai Gozani took the reins as CEO of NeuroMetrix Inc’s (NASDAQ:NURO) and grew market cap to US$9.86M recently. Recognizing whether CEO incentives are aligned with shareholders is a crucial partRead More...

  • NeuroMetrix Inc (NASDAQ:NURO): What Does It Mean For Your Portfolio?
    Simply Wall St.27 days ago

    NeuroMetrix Inc (NASDAQ:NURO): What Does It Mean For Your Portfolio?

    For NeuroMetrix Inc’s (NASDAQ:NURO) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. Every stock in theRead More...

  • ACCESSWIRElast month

    Free Technical Snapshots for Ekso Bionics and Three More Medical Supplies Stocks

    LONDON, UK / ACCESSWIRE / May 11, 2018/ If you want a free Stock Review on EKSO sign up now at www.wallstequities.com/registration. WallStEquities.com has initiated research coverage on Ekso Bionics Holdings Inc. (NASDAQ: EKSO), Haemonetics Corp. (NYSE: HAE), Hill-Rom Holdings Inc. (NYSE: HRC), and NeuroMetrix Inc. (NASDAQ: NURO). Companies in the Medical Instruments and Supplies Manufacturing industry primarily research, develop, and produce nonelectronic medical, surgical, dental, and veterinary instruments and apparatus, such as syringes, anesthesia apparatus, blood transfusion equipment, catheters, surgical clamps, and medical thermometers.

  • GlobeNewswire2 months ago

    Preliminary Results from Quell Chronic Low Back Pain Study to be Presented at World Institute of Pain World Congress

    NeuroMetrix, Inc. (NURO), today reported that preliminary results from a study of Quell® wearable pain relief in chronic low back pain will be presented at the 9th World Congress of the World Institute of Pain in Dublin, Ireland May 9-12, 2018. Subjects in the experimental group exhibited reduced pain interference with function and pain catastrophizing compared to the control group. Subjects in the experimental group with greater sensitivity on quantitative sensory testing had more disability and higher Quell use, but sensitivity did not predict pain outcomes.

  • GlobeNewswire2 months ago

    NeuroMetrix, Inc. to Participate in Upcoming Disruptive Growth & Healthcare Conference in New York City

    WALTHAM, Mass., May 01, 2018-- NeuroMetrix, Inc., announced today that it will be participating in the 3rd annual Disruptive Growth & Healthcare Conference in New York City on May 8-9, 2018 sponsored by ...

  • GlobeNewswire2 months ago

    NeuroMetrix to Present Quell Data at Upcoming American Academy of Pain Medicine Annual Meeting

    WALTHAM, Mass., April 24, 2018-- NeuroMetrix, Inc. today reported that it will present two scientific posters at the upcoming 2018 American Academy of Pain Medicine Annual Meeting to be held in Vancouver, ...

  • GlobeNewswire2 months ago

    NeuroMetrix Reports Q1 2018 Financial Results

    WALTHAM, Mass., April 19, 2018-- NeuroMetrix, Inc., today reported financial and business highlights for the quarter ended March 31, 2018.. The Company develops and markets novel therapies, based on neurostimulation ...

  • ACCESSWIRE2 months ago

    NeuroMetrix, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / April 19, 2018 / NeuroMetrix, Inc. (NASDAQ: NURO ) will be discussing their earnings results in their Q1 Earnings Call to be held on April 19, 2018 at 8:00 AM Eastern Time. ...

  • GlobeNewswire2 months ago

    NeuroMetrix to Present Data on Quell Sleep Monitoring Technology at Upcoming American Academy of Neurology Annual Meeting

    NeuroMetrix, Inc. (NURO) today reported that it will present a scientific poster at the upcoming 2018 American Academy of Neurology (AAN) Annual Meeting to be held in Los Angeles, CA, April 21-27. The poster is titled: “Pilot Study of Sleep/Wake Classification by Leg-Worn Actigraphy”, which can be viewed here: Pilot Study of Sleep/Wake Classification by Leg-Worn Actigraphy. The purpose of this study was to assess the accuracy of the sleep monitoring technology in the Quell® device by comparison to gold standard polysomnography.

  • GlobeNewswire2 months ago

    NeuroMetrix, Inc. Announces Date for 2018 First Quarter Financial Results Conference Call

    WALTHAM, Mass., April 11, 2018-- NeuroMetrix, Inc. announced today that it plans to issue its 2018 first quarter financial results before the opening of the market on Thursday, April 19, 2018. The Company ...

  • GlobeNewswire2 months ago

    NeuroMetrix Reports Results of Large Clinical Study of Quell Wearable Pain Relief

    WALTHAM, Mass., April 10, 2018-- NeuroMetrix, Inc., today reported publication of results from a clinical study of Quell ® in the Journal of Pain Research. The paper is titled“ Effectiveness of fixed-site ...

  • Should You Buy NeuroMetrix Inc (NASDAQ:NURO) Now?
    Simply Wall St.3 months ago

    Should You Buy NeuroMetrix Inc (NASDAQ:NURO) Now?

    NeuroMetrix Inc (NASDAQ:NURO), a medical equipment company based in United States, saw a double-digit share price rise of over 10% in the past couple of months on the NasdaqCM. AsRead More...

  • GuruFocus.com4 months ago

    NeuroMetrix Inc (NURO) Files 10-K for the Fiscal Year Ended on December 31, 2017

    NeuroMetrix Inc (NASDAQ:NURO) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017.

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of NURO earnings conference call or presentation 25-Jan-18 1:00pm GMT

    Q4 2017 NeuroMetrix Inc Earnings Call

  • ACCESSWIRE5 months ago

    Unknown BTCY May Have Big Upside Ahead of Likely Near-Term FDA Approval

    Healthcare as an industry will only continue to grow and offers an exceptional place to invest. Drug stocks face a historically high chance of failure, but medical devices are an attractive addition for ...

  • Here’s Why Neurometrix Inc Rose as Much as 60% Today
    SmarterAnalyst5 months ago

    Here’s Why Neurometrix Inc Rose as Much as 60% Today

    Shares of Neurometrix Inc (NASDAQ:NURO) rocketed more than 60% higher at one point Wednesday morning after the healthcare company announced a new collaboration with GlaxoSmithKline plc (ADR) (NYSE:GSK), involving Quell, the company's over-the-counter, 100% drug free chronic pain relief wearable. Specifically, GSK Consumer Healthcare acquires exclusive ownership of Quell technology for markets outside the U.S. Neurometrix will receive a payment of $5 million for the assets relating to Quell technology for markets outside the U.S and up to $21.5 million, upon the achievement of certain development and commercialization milestones. Investors will need to wait to see more precise details, but for a penny stock such as Neurometrix, this is pretty amazing no matter the exact dollar amount.

  • GuruFocus.com5 months ago

    7 Stocks Move in Premarket Trade Wednesday

    Five stocks up, two down